Literature DB >> 7231460

Female reproductive potential after treatment for Hodgkin's disease.

S J Horning, R T Hoppe, H S Kaplan, S A Rosenberg.   

Abstract

The probability of maintaining ovarian function, becoming pregnant, and delivering a normal child is important to young women anticipating successful therapy for Hodgkin's disease. In this study, reproductive function was retrospectively examined in 103 women 40 years old or younger who had undergone treatment for Hodgkin's disease with total-lymphoid irradiation (TLI) alone, combination chemotherapy, or combined TLI and chemotherapy. Infertility was directly related to gonadal exposure to therapy and to age at treatment. Twenty women became pregnant after receiving total-nodal irradiation or combination chemotherapy or both. No fetal wastage occurred, and no birth defects were seen in the 24 infants born to these women. Even after intensive treatment programs, women successfully treated for Hodgkin's disease have become pregnant and delivered phenotypically normal children.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7231460     DOI: 10.1056/NEJM198106043042301

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  28 in total

Review 1.  Treating cancer patients. Practical monitoring and management of therapy-related complications.

Authors:  M Brigden; M McKenzie
Journal:  Can Fam Physician       Date:  2000-11       Impact factor: 3.275

2.  BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group.

Authors:  Kara M Kelly; Richard Sposto; Raymond Hutchinson; Vickie Massey; Kathleen McCarten; Sherrie Perkins; Mark Lones; Doojduen Villaluna; Michael Weiner
Journal:  Blood       Date:  2010-11-15       Impact factor: 22.113

3.  Long-term survival among patients with Hodgkin's lymphoma who developed breast cancer: a population-based study.

Authors:  Michael T Milano; Huilin Li; Mitchell H Gail; Louis S Constine; Lois B Travis
Journal:  J Clin Oncol       Date:  2010-10-25       Impact factor: 44.544

4.  Prolonged amenorrhea associated with total nodal irradiation for Hodgkin's disease.

Authors:  M Y Halyard; J L Cornella; G L Grado; N R Rizzo
Journal:  J Natl Med Assoc       Date:  1996-06       Impact factor: 1.798

5.  Oocyte donation treats infertility in survivors of malignancies: ten-year experience.

Authors:  S M Kavic; M V Sauer
Journal:  J Assist Reprod Genet       Date:  2001-03       Impact factor: 3.412

6.  Gonadal function of young adults after therapy of malignancies during childhood or adolescence.

Authors:  H L Müller; M Klinkhammer-Schalke; B Seelbach-Göbel; A A Hartmann; J Kühl
Journal:  Eur J Pediatr       Date:  1996-09       Impact factor: 3.183

7.  Gynecologic complication of chronic graft-versus-host disease: Vaginal obstruction.

Authors:  Junsik Park; Tae-Hee Kim; Hae-Hyeog Lee; Soo-Ho Chung; Daegeun Lee
Journal:  Obstet Gynecol Sci       Date:  2013-07-15

8.  Impact of ovarian transposition before pelvic irradiation on ovarian function among long-term survivors of childhood Hodgkin lymphoma: A report from the St. Jude Lifetime Cohort Study.

Authors:  Israel Fernandez-Pineda; Andrew M Davidoff; Lu Lu; Bhaskar N Rao; Carmen L Wilson; D Kumar Srivastava; James L Klosky; Monica L Metzger; Matthew J Krasin; Kirsten K Ness; Ching-Hon Pui; Leslie L Robison; Melissa M Hudson; Charles A Sklar; Daniel M Green; Wassim Chemaitilly
Journal:  Pediatr Blood Cancer       Date:  2018-05-11       Impact factor: 3.167

Review 9.  Bone mineral density deficits and fractures in survivors of childhood cancer.

Authors:  Carmen L Wilson; Kirsten K Ness
Journal:  Curr Osteoporos Rep       Date:  2013-12       Impact factor: 5.096

10.  Menses resumption after cancer treatment-induced amenorrhea occurs early or not at all.

Authors:  Melanie H Jacobson; Ann C Mertens; Jessica B Spencer; Amita K Manatunga; Penelope P Howards
Journal:  Fertil Steril       Date:  2015-12-01       Impact factor: 7.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.